Norges Bank acquired a new position in ChemoCentryx, Inc. (NASDAQ:CCXI) during the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 464,097 shares of the biopharmaceutical company’s stock, valued at approximately $28,737,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Valeo Financial Advisors LLC purchased a new position in shares of ChemoCentryx in the fourth quarter worth approximately $37,000. Penserra Capital Management LLC increased its position in ChemoCentryx by 169.5% during the fourth quarter. Penserra Capital Management LLC now owns 1,590 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 1,000 shares during the period. Nisa Investment Advisors LLC increased its position in ChemoCentryx by 19.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,130 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 350 shares during the period. Pacer Advisors Inc. increased its position in ChemoCentryx by 39.9% during the fourth quarter. Pacer Advisors Inc. now owns 2,259 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 644 shares during the period. Finally, Captrust Financial Advisors increased its position in ChemoCentryx by 1,120.0% during the fourth quarter. Captrust Financial Advisors now owns 3,050 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 2,800 shares during the period. 80.67% of the stock is currently owned by institutional investors.

Shares of NASDAQ:CCXI opened at $45.29 on Wednesday. The company’s fifty day moving average is $53.22 and its 200-day moving average is $57.91. The company has a market capitalization of $3.16 billion, a PE ratio of -67.60 and a beta of 1.70. The company has a debt-to-equity ratio of 0.05, a quick ratio of 10.12 and a current ratio of 10.12. ChemoCentryx, Inc. has a 52 week low of $44.32 and a 52 week high of $70.29.

ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings results on Sunday, February 28th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.10). The company had revenue of $4.36 million for the quarter, compared to analyst estimates of $8.92 million. ChemoCentryx had a negative return on equity of 17.23% and a negative net margin of 58.10%. On average, analysts forecast that ChemoCentryx, Inc. will post -0.72 EPS for the current year.

In other ChemoCentryx news, Treasurer Markus J. Cappel sold 1,375 shares of the company’s stock in a transaction dated Monday, January 25th. The shares were sold at an average price of $67.03, for a total transaction of $92,166.25. Following the transaction, the treasurer now directly owns 87,201 shares in the company, valued at approximately $5,845,083.03. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Pui San Kwan sold 4,184 shares of the company’s stock in a transaction dated Monday, January 25th. The shares were sold at an average price of $65.00, for a total transaction of $271,960.00. Following the transaction, the insider now owns 4,066 shares in the company, valued at $264,290. The disclosure for this sale can be found here. In the last quarter, insiders have sold 79,185 shares of company stock worth $5,215,736. 9.30% of the stock is owned by corporate insiders.

Several brokerages have issued reports on CCXI. Raymond James boosted their price target on shares of ChemoCentryx from $119.00 to $120.00 and gave the company a “strong-buy” rating in a report on Monday, March 8th. Stifel Nicolaus began coverage on shares of ChemoCentryx in a report on Monday, March 8th. They issued a “buy” rating and a $93.00 price target on the stock. HC Wainwright boosted their price target on shares of ChemoCentryx from $83.00 to $101.00 and gave the company a “buy” rating in a report on Tuesday, March 2nd. Finally, TheStreet lowered shares of ChemoCentryx from a “c-” rating to a “d” rating in a report on Tuesday, March 2nd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $78.60.

About ChemoCentryx

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.

Read More: Shanghai Stock Exchange Composite Index

Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI).

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.